Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06222892 · ClinicalTrials.gov registry record · Phase 1
A Study of Camlipixant in Male and Female Healthy Participants and Participants With Hepatic Impairment Aged 18-75 Years of Age
A Phase 1 study of Cough, sponsored by Bellus Health Inc. - a GSK company.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
- 3
- Study locations
NCT06222892 is a Phase 1 study of Cough that has completed, run by Bellus Health Inc. - a GSK company. The registered enrollment target is 32 participants, below the 219-participant average among 12 other Cough trials with a reported enrollment target (85% lower). The trial reports 3 study locations across 2 states.
The verdict
NCT06222892, a Phase 1 study of Cough, has completed, sponsored by Bellus Health Inc. - a GSK company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to assess the effect of Hepatic impairment (HI) on the Pharmacokinetic (PK) profile and safety of Camlipixant.
Conditions Studied
Interventions
- DRUG Camlipixant
Study Locations (3)
Florida
- GSK Investigational Site - Miami
- GSK Investigational Site - Orlando
Texas
- GSK Investigational Site - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2024-02-02 |
| Est. Completion | 2024-12-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06222892
The ClinicalTrials.gov registry entry for NCT06222892 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 219-participant average among 12 other Cough trials with a reported enrollment target (85% lower). The listed sponsor is Bellus Health Inc. - a GSK company, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cough appearing as the primary indexed condition, and to 1 intervention - of which Camlipixant is the first listed.
NCT06222892 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Florida, Texas.
Frequently Asked Questions
What is clinical trial NCT06222892 about?
NCT06222892 is a clinical study titled "A Study of Camlipixant in Male and Female Healthy Participants and Participants With Hepatic Impairment Aged 18-75 Years of Age". The purpose of this study is to assess the effect of Hepatic impairment (HI) on the Pharmacokinetic (PK) profile and safety of Camlipixant.
What is the current status of trial NCT06222892?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2024-02-02. Estimated completion is 2024-12-30.
What conditions does trial NCT06222892 study?
This clinical trial studies the following conditions: Cough.
What interventions are being tested in trial NCT06222892?
The interventions under investigation include: Camlipixant (DRUG).
Who is sponsoring clinical trial NCT06222892?
This trial is sponsored by Bellus Health Inc. - a GSK company, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06222892 being conducted?
This trial has 3 study locations across Florida, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cough
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Cough Desensitization Therapy: Pilot 2
COMPLETED · Phase 1
-
Effect of Honey and Dextromethorphan on Nocturnal Cough and Sleep
COMPLETED · Phase 1
-
A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
RECRUITING · Phase 3
-
Office-Based Superior Laryngeal Nerve Block for Treatment of Neurogenic Cough
RECRUITING
-
The Mechanism Versus PPI Trial
RECRUITING · Phase 4
-
Stimulation of the Larynx to Treat Unexplained Chronic Cough
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.